Conventional CAR T manufacturing takes weeks, requires a functioning leukapheresis product, and still fails a meaningful share of heavily pretreated patients before a single cell is infused. Umoja Biopharma is betting its entire platform on collapsing that process to a single intravenous dose, and the FDA just cleared the path for its second attempt to prove it. The agency has cleared an IND for UB-VV400, a CD22-directed in vivo CAR T candidate for adults with relapsed or refractory B cell malignancies, with first dosing targeted for Q3 2026.
UB-VV400 uses Umoja’s VivoVec lentiviral vector platform to reprogram a patient’s T cells directly inside the body, bypassing the ex vivo manufacturing chain entirely. What distinguishes this program clinically is not just the delivery method but the target and the patient population it is designed to serve. CD22 is a well-validated B cell antigen, and the VIBRANT-1 Phase 1/2 trial explicitly includes patients who have already progressed after prior CAR T cell treatment, a group that current approved cellular therapies effectively cannot recapture. The open-label, dose-escalation study will evaluate safety, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of UB-VV400 in combination with rapamycin, the latter chosen for its immunomodulatory properties that may shape the in vivo CAR T expansion window.
The timing carries additional weight because the broader relapsed B cell malignancy landscape is becoming more crowded at earlier lines. The European Commission granted marketing authorization in July 2026 for epcoritamab in combination with lenalidomide and rituximab for relapsed or refractory follicular lymphoma, illustrating the pace of competition in this space. Umoja’s differentiation rests not on targeting an underserved antigen in isolation but on the manufacturing thesis: if in vivo generation works, it removes access barriers that currently exclude patients who deteriorate during the manufacturing wait or who lack adequate starting material for collection.
Umoja has also disclosed that initial clinical data from an investigator-initiated trial of UB-VV400 conducted in China will be presented at a major medical meeting in the second half of 2026. That readout is the number to watch. Preclinical signals and IND clearance establish mechanism and regulatory feasibility; the China cohort data will be the first human evidence of whether in vivo CD22-directed CAR T expansion actually produces antitumor responses at a magnitude that justifies the platform’s promise over the ex vivo standard.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
